Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma

NCT00859404 is registered in ClinicalTrials.gov with Glenmark Pharmaceuticals Europe Ltd. (R&D) as lead sponsor.

NCT NCT00859404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00859404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma
Lead sponsor
Glenmark Pharmaceuticals Europe Ltd. (R&D)
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2008
Completion date
January 31, 2010
Enrollment
282 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma